Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984449 | 0.82 | DPP4 (0.44) | DPP4FAPDPP8KCNH2CYP2D6 | |
| SCHEMBL13026679 | 0.78 | DPP4 (0.43) | DPP4FAPDPP8 | |
| SCHEMBL8203769 | 0.70 | DPP4 (0.47) | DPP4FAPDPP8 | |
| SCHEMBL12840805 | 0.65 | DPP4 (0.43) | DPP4FAPDPP8 | |
| SCHEMBL17624451 | 0.63 | PDE10A (0.35) | — | |
| SCHEMBL13026676 | 0.63 | DPP4 (0.43) | DPP4FAPDPP8 | |
| SCHEMBL8205832 | 0.61 | KDM4E (0.36) | DPP4FAPDPP8 | |
| SCHEMBL17624354 | 0.59 | ALOX15 (0.44) | — | |
| SCHEMBL10306805 | 0.59 | DPP4 (0.32) | DPP4FAPDPP8 | |
| SCHEMBL10280071 | 0.58 | PLK1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855206-B2 | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| WO-2008060488-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056550-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 31/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.